Clinical Trial Update: AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AK117, an anti-CD47 therapy, in combination with an anti-EGFR agent for recurrent/metastatic head and neck squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• AK117 (AK117)
• Anti-EGFR

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING